Clark Capital Management Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$650K Buy
23,157
+276
+1% +$7.35K ﹤0.01% 349
2025
Q4
$570K Sell
22,881
-4,399
-16% -$111K ﹤0.01% 355
2025
Q3
$695K Sell
27,280
-2,519
-8% -$62.2K ﹤0.01% 318
2025
Q2
$722K Sell
29,799
-2,233
-7% -$52.1K 0.01% 311
2025
Q1
$812K Buy
32,032
+978
+3% +$25.6K 0.01% 310
2024
Q4
$824K Sell
31,054
-1,186
-4% -$32.2K 0.01% 309
2024
Q3
$933K Buy
32,240
+461
+1% +$13.4K 0.01% 301
2024
Q2
$889K Buy
31,779
+15,525
+96% +$427K 0.01% 286
2024
Q1
$451K Sell
16,254
-7,555
-32% -$210K ﹤0.01% 333
2023
Q4
$685K Sell
23,809
-686,282
-97% -$20.7M 0.01% 298
2023
Q3
$23.6M Buy
710,091
+13,268
+2% +$469K 0.24% 134
2023
Q2
$25.6M Buy
696,823
+20,162
+3% +$785K 0.23% 128
2023
Q1
$27.6M Buy
676,661
+11,585
+2% +$500K 0.31% 118
2022
Q4
$34.1M Buy
665,076
+25,784
+4% +$1.24M 0.31% 88
2022
Q3
$28M Sell
639,292
-302,292
-32% -$14.7M 0.37% 80
2022
Q2
$49.4M Buy
941,584
+109,245
+13% +$5.57M 0.65% 28
2022
Q1
$43.1M Buy
832,339
+253,926
+44% +$13.2M 0.48% 48
2021
Q4
$34.2M Buy
578,413
+568,479
+5,723% +$28.2M 0.42% 85
2021
Q3
$427K Buy
9,934
+427
+4% +$18.9K 0.01% 288
2021
Q2
$372K Buy
9,507
+1,484
+18% +$57.7K 0.01% 309
2021
Q1
$291K Sell
8,023
-562,035
-99% -$20M ﹤0.01% 317
2020
Q4
$21M Sell
570,058
-40,095
-7% -$1.47M 0.35% 124
2020
Q3
$21.2M Sell
610,153
-740
-0.1% -$25.9K 0.4% 105
2020
Q2
$19M Buy
610,893
+4,344
+0.7% +$148K 0.35% 114
2020
Q1
$18.8M Sell
606,549
-8,403
-1% -$286K 0.48% 75
2019
Q4
$22.9M Buy
614,952
+6,747
+1% +$240K 0.48% 78
2019
Q3
$20.7M Sell
608,205
-671,837
-52% -$24.4M 0.47% 85
2019
Q2
$52.6M Buy
1,280,042
+378,310
+42% +$15M 1.11% 19
2019
Q1
$36.3M Sell
901,732
-535,687
-37% -$21.5M 0.87% 37
2018
Q4
$59.5M Sell
1,437,419
-60,577
-4% -$2.51M 1.6% 10
2018
Q3
$62.6M Buy
1,497,996
+1,486,759
+13,231% +$57.2M 1.59% 10
2018
Q2
$387K Sell
11,237
-2,676
-19% -$91.4K 0.01% 239
2018
Q1
$468K Sell
13,913
-685
-5% -$23.5K 0.01% 244
2017
Q4
$502K Buy
14,598
+3,187
+28% +$109K 0.02% 234
2017
Q3
$386K Buy
11,411
+1,467
+15% +$47.1K 0.01% 259
2017
Q2
$317K Sell
9,944
-2,018
-17% -$63.6K 0.01% 238
2017
Q1
$388K Sell
11,962
-713,964
-98% -$22.5M 0.02% 242
2016
Q4
$22.4M Buy
725,926
+103,384
+17% +$3.16M 1.16% 15
2016
Q3
$20M Buy
622,542
+109,731
+21% +$3.67M 1.15% 15
2016
Q2
$17.1M Buy
512,811
+221,775
+76% +$7.08M 1.11% 15
2016
Q1
$8.18M Sell
291,036
-79,520
-21% -$2.27M 0.63% 59
2015
Q4
$11.3M Buy
370,556
+338,213
+1,046% +$10.6M 0.92% 23
2015
Q3
$964K Buy
32,343
+1,926
+6% +$61.8K 0.09% 172
2015
Q2
$968K Sell
30,417
-1,830
-6% -$59.6K 0.09% 174
2015
Q1
$1.06M Sell
32,247
-2,176
-6% -$69.2K 0.1% 173
2014
Q4
$1.02M Sell
34,423
-7,763
-18% -$223K 0.09% 134
2014
Q3
$1.18M Sell
42,186
-3,756
-8% -$105K 0.1% 120
2014
Q2
$1.29M Sell
45,942
-247,328
-84% -$7.05M 0.11% 125
2014
Q1
$8.94M Buy
293,270
+7,227
+3% +$215K 0.77% 31
2013
Q4
$8.31M Buy
286,043
+11,816
+4% +$344K 0.69% 31
2013
Q3
$7.47M Buy
274,227
+14,971
+6% +$407K 0.59% 38
2013
Q2
$6.89M Buy
+259,256
New +$7.16M 0.63% 36

Other funds holding PFE

Clark Capital Management Group's PFE Position: Q1 2026 in Review

Clark Capital Management Group increased its Pfizer (PFE) stake by 1.2% in Q1 2026, buying an estimated $7.35K and bringing the position to 23,157 shares worth $650K. The position accounts for ﹤0.01% of the portfolio, ranked #349.

Clark Capital Management Group first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $62.6M in Q3 2018. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Clark Capital Management Group held 23,157 shares of Pfizer worth $650K as of Q1 2026.
  • Clark Capital Management Group bought 276 Pfizer shares in Q1 2026, an estimated $7.35K.
  • Pfizer made up ﹤0.01% of Clark Capital Management Group's portfolio in Q1 2026, its #349 holding.
  • Clark Capital Management Group first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Clark Capital Management Group's Pfizer position peaked at $62.6M in Q3 2018.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Clark Capital Management Group's 13F filing for Q1 2026, filed 15 May 2026.